Tanovea ® (rabacfosadine for injection) is the first and only FDA fully approved treatment for canine lymphoma, offering renewed confidence for a different approach at first rescue. Tanovea’s MOA is different from commonly used agents in canine lymphoma. 1-4.

Tanovea is a promising new anti-cancer drug designed to treat canine lymphoma. Most cancer treatments are initially targeted for human use and then secondarily modified for animals; however, Tanovea was developed specifically for dogs, heralding a new ear in veterinary research and drug discovery.

Jul 19, 2021 · Elanco Animal Health Incorporated (NYSE: ELAN) announced that the FDA has granted full approval of Tanovea for the treatment of lymphoma in dogs, making this the first conditionally approved new animal drug for dogs that has ever advanced from a conditional to full FDA approval under the FDA’s Minor Use and Minor Species (MUMS) program.

Rabacfosadine, sold under the brand name Tanovea, is a guanine nucleotide analog used for the treatment of lymphoma in dogs. [1] It was developed by Gilead Sciences as GS-9219. [2] The active form of rabacfosadine is a chain-terminating inhibitor of the major deoxyribonucleic acid (DNA) polymerases.

Jul 15, 2021 · Today, the U.S. Food and Drug Administration fully approved Tanovea (rabacfosadine injection) to treat lymphoma in dogs. Lymphoma, also called lymphosarcoma, is a type of cancer that can affect...

Sep 28, 2021 · Tanovea (rabacfosadine) is the first conditionally approved animal medication to receive the FDA's full approval to treat lymphoma in dogs. Learn more from GoodRx about this chemotherapy injection for canine lymphoma.

Mar 2, 2025 · TANOVEA is indicated for the treatment of lymphoma in dogs. Dosage and Administration. Always provide the Client Information Sheet to the dog owner with each dose administration. Administer TANOVEA at 1 mg/kg body weight as a 30-minute intravenous infusion, once every three weeks, for up to five doses.

Tanovea is indicated for the treatment of lymphoma in dogs. Always provide the Client Information Sheet to the dog owner with each dose administration. Administer Tanovea at 1 mg/kg body weight as a 30-minute intravenous infusion, once every three weeks, for up to five doses.

Sep 27, 2017 · What is TANOVEA-CA1? • TANOVEA-CA1 is an acyclic nucleotide phosphonate used to treat lymphoma, a form of cancer that affects dogs. • The active ingredient in TANOVEA-CA1 is rabacfosadine, a substance that works by killing rapidly growing tumor cells. What should I tell my veterinarian about my dog before he/she receives TANOVEA-CA1?

Apr 19, 2018 · Basically, Tanovea® preferentially targets activated or cancerous lymphoid cells. Once inside the cells, Tanovea® undergoes enzymatic changes to become PMEGpp, and this compound inhibits DNA synthesis and repair.